✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating

On June 4, analysts at Cantor Fitzgerald began coverage on GH Research PLC (NASDAQ:GHRS)’s stock with an “Overweight” rating and a price objective of $25.00, as reported by The Fly.

A biochemist in a laboratory conducting research on a new psychiatric therapy.

The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative impact of psychedelics on numerous mental health disorders, including depression, PTSD, and anxiety.

As per the firm, the total addressable market (TAM) for psychedelics can eventually touch $50 billion annually, potentially serving 1 to 1.5 million patients each year. As a result, the analysts opine that there is a significant opportunity for multiple companies to succeed in this space, providing a range of psychedelic substances and novel synthetic products.

GH Research PLC’s lead product candidate, GH001, is formulated for mebufotenin administration through a proprietary inhalation approach. Based on the observed clinical activity in the Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), GH Research PLC opines that GH001 can change the way treatment-resistant depression (TRD) is treated.

GH Research PLC had cash, cash equivalents, other financial assets, and marketable securities of $315.3 million as of March 31, 2025, as compared to $182.6 million as of December 31, 2024.

GH Research PLC is a clinical-stage biopharmaceutical company that is focused on transforming the treatment of psychiatric and neurological disorders.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now